Skip to content

A prospective, multicentre, randomised, crossover controlled clinical trial of cervical colposcopy image-assisted triage software for the diagnosis of cervical lesions

A prospective, multicentre, randomised, crossover controlled clinical trial of cervical colposcopy image-assisted triage software for the diagnosis of cervical lesions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400090474
Enrollment
Unknown
Registered
2024-09-30
Start date
2024-10-01
Completion date
Unknown
Last updated
2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical disease

Interventions

Gold Standard:After completion of colposcopy, clinical diagnosis results (such as colposcopy list, etc.) and pathological results (if any) of enrolled subjects were collected to establish a gold stand
Positive diagnosis results must be accompanied by pathological examination reports, including CIN1, CIN2, CIN3, AIS (adenocarcinoma in situ), squamous cell carcinoma and adenocarcinoma. Negative diagn
Expert group composition requirements: 3 people, deputy chief physician and above. First, two experts were evaluated back to back, and if the results were consistent, the output was the gold standard
If the results are inconsistent, the arbitration expert (the third expert) will evaluate the results of the arbitration expert as the gold standard.
Index test:Sensitivity and specificity of cervical lesion diagnosis in experimental group (software-assisted investigator reading) and control group (investigator independent reading) Accuracy, negati

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: ?18 years old = age =64 years old, sexual life history of women; ?It has an intact cervix; ?Conform to colposcopy criteria, plan to undergo colposcopy (Conform to one of these criteria): 1)Abnormal cervical cancer screening:a)ytology ASC-US with hr-hpv infection;b)Cytology LSIL and more serious; c)hr-hpv16/18 infection;d)hr-hpv infection persists for more than one year; 2)Symptoms or signs suggest suspected cervical cancer, abnormal bleeding in the lower genital tract, bleeding after repeated intercourse, or unexplained vaginal drainage; ?Volunteer to participate in the trial and sign the informed consent; ?Having full capacity for civil conduct.

Exclusion criteria

Exclusion criteria: ? There is a history of sexual life, vaginal irrigation, and vaginal medication 48 hours before the examination; ? History of cervical surgery (including cervical conectomy, hysterectomy, cervical physical therapy and chemoradiation, etc.); ? Pregnant women; (4) Colposcopic images are not clear, affecting interpretation; ? Participate in other clinical trials have not been out of the group; ? Researchers believe that it is not suitable for inclusion (such as colposcopy is not satisfied, etc.).

Design outcomes

Primary

MeasureTime frame
Sensitivity and specificity of cervical lesion diagnosis in experimental group (software-assisted investigator reading) and control group (investigator independent reading);

Secondary

MeasureTime frame
Accuracy, negative predictive value and positive predictive value of experimental group (software-assisted researcher reading) and control group (researcher independent reading);Sensitivity and specificity of software independent film reading results;The test software recommended the accuracy of the biopsy site location;Test software performance evaluation;

Countries

China

Contacts

Public ContactLan.Zhu

Peking Union Medical College Hospital

zhu_julie@vip.sina.com+86 139 1171 4696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026